Home › Funds › ARMISTICE CAPITAL, LLC › AUTL

ARMISTICE CAPITAL, LLC position in AUTL

AUTOLUS THERAPEUTICS LTD · Health Care

ARMISTICE CAPITAL, LLC reported holding 15,000,000 shares of AUTL (AUTOLUS THERAPEUTICS LTD) in its Q2 2026 13F filing — a position valued at US$24.0M, representing 0.32% of its reported portfolio and ranking #46 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed AUTL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)15.00M sh
Reported value held$24.00M
Portfolio Weight0.32%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's AUTL position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in AUTL in Q3 2023 at 6,900,000 shares (US$16.1M). The position peaked in Q4 2025 at 17,500,000 shares, worth US$34.8M. Across 12 filings, ARMISTICE CAPITAL, LLC increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 15,000,000 shares valued at US$24.0M — a reduction of -800,000 shares quarter over quarter.. Notable position changes include a 44% trim in Q4 2023 (shares were roughly flat over the following quarter), a 34% increase in Q2 2024 (shares rose 4% over the following quarter), a 34% increase in Q4 2024 (shares fell 34% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 6.90M $16.08M New
Q4 2023 3.85M $24.79M Reduce
Q1 2024 4.67M $29.81M Add
Q2 2024 6.25M $21.75M Add
Q3 2024 6.87M $24.95M Add
Q4 2024 9.20M $21.62M Add
Q1 2025 11.00M $17.05M Add
Q2 2025 12.00M $27.36M Add
Q3 2025 15.60M $25.43M Add
Q4 2025 17.50M $34.83M Add
Q1 2026 15.80M $21.80M Reduce
Q2 2026 15.00M $24.00M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AUTL and 13F data

AUTL (AUTOLUS THERAPEUTICS LTD) is a Health Care company. 18 other funds we track also report a position in AUTL — the largest reported positions include MAK CAPITAL ONE LLC (US$53.8M), Syncona Portfolio Ltd (US$26.6M), Tetragon Partners GP Ltd (US$15.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AUTL

All AUTL fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held AUTL?

ARMISTICE CAPITAL, LLC has disclosed AUTL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ARMISTICE CAPITAL, LLC's current position in AUTL?

As of Q2 2026, ARMISTICE CAPITAL, LLC holds 15.00M shares of AUTL (AUTOLUS THERAPEUTICS LTD), valued at $24.00M, representing 0.32% of its reported portfolio and ranking #46.

Has ARMISTICE CAPITAL, LLC been buying or selling AUTL?

In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC reduced its position in AUTL. The position peaked in Q4 2025 at 17.50M shares.

Which other funds hold AUTL?

Other major institutional holders of AUTL include MAK CAPITAL ONE LLC, Syncona Portfolio Ltd, Tetragon Partners GP Ltd, among 18 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.